The abstract is read at the publisher; the summary is JClub's.
BCMA-targeted therapies in adults with autoimmune diseases are linked to reduced vaccine-specific antibody titres and lower total immunoglobulin levels, informing revaccination timing.
- Why it matters: Long-term humoral immunity after B-cell immune-reset therapies is uncertain, creating a need for practical guidance on whether and when to revaccinate.
- What they did: The authors reviewed existing clinical evidence on BCMA-targeting effects on antivaccine titres and used oncology data to frame expectations under BCMA-directed cell depletion.
- The result: They propose a pragmatic revaccination approach using minimal serologic monitoring, with future studies needed to refine optimal timing and whether revaccination is necessary.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.